Tetrahydrouridine, also known as THU, is an inhibitor of nucleotide metabolism and is under investigation for use in the treatment of cancer. THU may be useful for researching potential treatments for high cytidine deaminase (CDA) expressing tumors as a competitive inhibitor of CDA. It is being evaluated alone or in combination with the DNA methyltransferase inhibitor, 5- fluoro-2’-deoxycytidine in animal models and clinical trials for diseases including cancer and mitochondrial DNA syndrome. It is also being evaluated in combination with cytosine arabinoside (ara-C, cytarabine) for acute myeloid leukemia and in combination with decitabine (DAC) for the treatment of sickle cell disease and β-thalassemia.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), and to obtain the following information:
To order an OEL/ADE monograph for Tetrahydrouridine, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’s OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.